The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial
Open accessAbstract
BACKGROUND: Maternal obesity is associated with increased birthweight, and obesity and premature mortality in adult offspring. The mechanism by which maternal obesity leads to these outcomes is not well understood, but maternal hyperglycaemia and insulin resistance are both implicated. We aimed to establish whether the insulin sensitising drug metformin improves maternal and fetal outcomes in obese pregnant women without diabetes. METHODS: We did this randomised, double-blind, placebo-controlled trial in antenatal clinics at 15 National Health Service hospitals in the UK. Pregnant women (aged ≥16 years) between 12 and 16 weeks' gestation who had a BMI of 30 kg/m(2) or more and normal glucose tolerance were randomly assigned (1:1), via a web-based computer-generated block randomisation procedure (block size of two to four), to receive oral metformin 500 mg (increasing to a maximum of 2500 mg) or matched placebo daily from between 12 and 16 weeks' gestation until delivery of the baby. Randomisation was stratified by study site and BMI band (30-39 vs ≥40 kg/m(2)). Participants, caregivers, and study personnel were masked to treatment assignment. The primary outcome was Z score corresponding to the gestational age, parity, and sex-standardised birthweight percentile of liveborn babies delivered at 24 weeks or more of gestation. We did analysis by modified intention to treat. This trial is registered, ISRCTN number 51279843. FINDINGS: Between Feb 3, 2011, and Jan 16, 2014, inclusive, we randomly assigned 449 women to either placebo (n=223) or metformin (n=226), of whom 434 (97%) were included in the final modified intention-to-treat analysis. Mean birthweight at delivery was 3463 g (SD 660) in the placebo group and 3462 g (548) in the metformin group. The estimated effect size of metformin on the primary outcome was non-significant (adjusted mean difference -0·029, 95% CI -0·217 to 0·158; p=0·7597). The difference in the number of women reporting the combined adverse outcome of miscarriage, termination of pregnancy, stillbirth, or neonatal death in the metformin group (n=7) versus the placebo group (n=2) was not significant (odds ratio 3·60, 95% CI 0·74-17·50; p=0·11). INTERPRETATION: Metformin has no significant effect on birthweight percentile in obese pregnant women. Further follow-up of babies born to mothers in the EMPOWaR study will identify longer-term outcomes of metformin in this population; in the meantime, metformin should not be used to improve pregnancy outcomes in obese women without diabetes. FUNDING: The Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council and National Institute for Health Research partnership.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure Trial profile *Change in eligibility from screening of notes to recruitment visit (unable to arrange recruitment visit before 16 weeks [n=26]), recruitment stopped before screening appointment (n=14), miscarriage (n=2), moved out of area (n=1), unable to provide informed consent because of difficulties with spoken English (n=5), own doctor or midwife advised against participation (n=4), duplicate note screening number issued in error (n=4). †3 months after birth.](/paper-figures/ddb4f26800dc402186a0f6627314255f/effect-of-metformin-on-maternal-and-fetal-outcomes-in-obese-pregnant-women-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the Fetal Medicine Foundation trial, women had a higher BMI (>35 kg/m2 vs. >30 kg/m2), were treated with a higher starting and maximum dose of metformin, and were more compliant than women in the EMPOWaR trial(95, 96).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“By contrast, in the EMPOWaR trial, compliance was defined as ingestion of at least one tablet for at least 29% of the days between randomization and delivery, and only 67% of women fulfilled this criterion(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In this trial, metformin had no significant effect on birth weight, maternal weight gain during gestation, preeclampsia, or combined adverse pregnancy outcomes, including miscarriage, termination of pregnancy, or fetal or neonatal death(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In this trial, metformin had no significant effect on birth weight, maternal weight gain during gestation, preeclampsia, or combined adverse pregnancy outcomes, including miscarriage, termination of pregnancy, or fetal or neonatal death(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In the Fetal Medicine Foundation trial, women had a higher BMI (>35 kg/m2 vs. >30 kg/m2), were treated with a higher starting and maximum dose of metformin, and were more compliant than women in the EMPOWaR trial(95, 96).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In this trial, metformin had no significant effect on birth weight, maternal weight gain during gestation, preeclampsia, or combined adverse pregnancy outcomes, including miscarriage, termination of pregnancy, or fetal or neonatal death(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“It is also noteworthy that only 13% (443/3329) of eligible patients consented to participate in the EMPOWaR study, whereas 47% (400/844) of eligible women were recruited to the Fetal Medicine Foundation study, making the latter group more representative of women who meet the study’s eligibility criteria and to whom the study’s results apply.”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In the Fetal Medicine Foundation trial, women had a higher BMI (>35 kg/m2 vs. >30 kg/m2), were treated with a higher starting and maximum dose of metformin, and were more compliant than women in the EMPOWaR trial(95, 96).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“By contrast, in the EMPOWaR trial, compliance was defined as ingestion of at least one tablet for at least 29% of the days between randomization and delivery, and only 67% of women fulfilled this criterion(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
In the citing paper
“In this trial, metformin had no significant effect on birth weight, maternal weight gain during gestation, preeclampsia, or combined adverse pregnancy outcomes, including miscarriage, termination of pregnancy, or fetal or neonatal death(95).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Metzger, B. E., Gabbe, S. G., Persson, B., Lowe, L. P., Dyer, A. R., Oats, J. J. N., & Buchanan, T. A. (2010) · Diabetes Care · doi:10.2337/dc10-0719 · Cited by 1,888
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Childhood predictors of adult obesity: a systematic review.
Parsons, T. J., Power, C., Logan, S., & Summerbell, C. (1999) · PubMed · Cited by 1,001
Birth Weight and Adult Hypertension, Diabetes Mellitus, and Obesity in US Men
Curhan, G. C., Willett, W. C., Rimm, E. B., Spiegelman, D. L., Ascherio, A., & Stampfer, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.12.3246 · Cited by 917
Maternal Body Mass Index and the Risk of Preeclampsia: A Systematic Overview
O'Brien, T., Ray, J. G., & Chan, W. (2003) · Epidemiology · doi:10.1097/00001648-200305000-00020 · Cited by 908
Catalano, P., & Ehrenberg, H. M. (2006) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00989.x · Cited by 828
Thangaratinam, S., Rogozinska, E., Jolly, K., Glinkowski, S., Roseboom, T., Tomlinson, J. W., Kunz, R., Mol, B. W., Coomarasamy, A., & Khan, K. S. (2012) · BMJ · doi:10.1136/bmj.e2088 · Cited by 802
Cited by
Sorted by citations
Items 201–262 of 262
Costa, D. N., Malek, R., & Davis, S. N. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2545929 · Cited by 2
Zhang, W., Ren, L., Du, J., Sun, R., Zhao, W., Song, X., Jiang, S., Wang, Z., & Wang, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1737337 · Cited by 2
Decoding Human Placental Cellular and Molecular Responses to Obesity and Fetal Growth
Jiang, H., Derisoud, E., Parreira, D., Taebnia, N., Jannig, P. R., Shafagh, R. Z., Zhao, A., Li, C., Ortíz, M., Maliqueo, M. A., et al. (2026) · Advanced Science · doi:10.1002/advs.202509691 · Cited by 2
Metformin: An emerging therapeutic approach for prevention and treatment of preeclampsia
Afghan, S., Quasimi, H., Alam, S., & Alam, I. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115048 · Cited by 2
Metformin in High Metabolic Risk Pregnancies — A Patient-Level Meta-Analysis
Mousa, A., Løvvik, T. S., Carlsen, S., Belsti, Y., Enticott, J., Tay, C. T., Nikkinen, H., Morin-Papunen, L. C., Tertti, K., Rönnemaa, T., et al. (2026) · NEJM Evidence · doi:10.1056/evidoa2500337 · Cited by 2
Self-citationLiu, H., Liu, Y., Wei, C., Zhang, S., & Xu, Y. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03760-z · Cited by 2
do Nascimento, I. B., Fleig, R., Silva, R. R. E., & Silva, J. C. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100280 · Cited by 2
Linder, T., Dressler‐Steinbach, I., Tura, A., & Göbl, C. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237197 · Cited by 2
Weight gain in pregnancy: can metformin steady the scales?
Adams, J. H., Poehlmann, J. R., Racine, J. L., Iruretagoyena, J. I., Eddy, A., Hoppe, K. K., Stewart, K. S., Rhoades, J. S., & Antony, K. M. (2022) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2022.2044775 · Cited by 2
Developmental Programming of Nonalcoholic Fatty Liver Disease (NAFLD)
Bruce, K. D., & Cagampang, F. R. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6386-7_12 · Cited by 1
Kumar, A., Muthukrishnan, J., Patel, A., & Kiran, B. C. (2025) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-025-02124-6 · Cited by 1
Role of Metformin in Preeclampsia: A Systematic Review
Anuja, M., Arthy, M., Jha, N., Ashok, M., Jha, A. K., & Sivaranjani, P. (2025) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-025-02194-6 · Cited by 1
Treatment of type 2 diabetes in pregnancy: Do we need to use metformin?
Fu, J. M., & Feig, D. S. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102027 · Cited by 1
Usevych, I. A., Oleshko, V. F., Kovaliuk, T. V., Maidannyk, I. V., & Rossovska, M. Y. (2025) · Experimental and Clinical Medicine · doi:10.35339/ekm.2025.94.3.uok · Cited by 1
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies
Fotheringham, P., McGee, R., Chang, R., Kennedy, D. S., & Simmons, D. S. (2026) · Drugs · doi:10.1007/s40265-025-02279-6 · Cited by 1
Maternal Obesity and Gestational Weight Gain as Determinants of Long-Term Health
Patel, N., & Poston, L. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6386-7_3 · Cited by 1
Early Pregnancy Support: Evidence-Based Management
Kandavel, V., & Quenby, S. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-42858-1_6 · Cited by 1
Self-citationFrequency of Pre-Eclampsia in Obese pregnant Females taking Metformin during Pregnancy
Wajid, R., Zubair, Z., Parveen, A., Ammara, & Masood, S. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs202317319 · Cited by 1
Bomba-Opon, D. A., Gutaj, P., Kędzia, M., Leszczyńska‐Gorzelak, B., Majewska, A., Radzicka, S., Stanirowski, P. J., & Wender-Ożegowska, E. (2023) · Ginekologia Polska · doi:10.5603/gpl.97361 · Cited by 1
Physical exercise and metformin in the prevention of pre-eclampsia: systematic review
do Nascimento, I. B., Nunes, M. M., & Fleig, R. (2020) · Fisioterapia em Movimento · doi:10.1590/1980-5918.033.ao41 · Cited by 1
Clara, U. S., Oliveira, C. P. L., da Fonseca, C. M., Clara, U. S., Silva, C. R., & das Ondas, U. (2022) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v38i1.13128 · Cited by 1
Pregnancy and metabolic syndrome of obesity
Barr, S., Nelson, S. M., & Huda, S. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817921-5.00015-1 · Cited by 1
Obesity and Diabetes in Pregnancy
McIntyre, D. H., Nitert, M. D., Barrett, H. L., & Callaway, L. K. (2017) · Wiley eBooks · doi:10.1002/9781119043805.ch7 · Cited by 1
Cell type-specific placental signatures in polyendocrine metabolic ovary syndrome and metforminPreprint
Jiang, H., Wang, X., Vanky, E., Parreira, D., Derisoud, E., Jannig, P. R., Nordenhök, E., Zhao, A., Li, C., Stridsklev, S., et al. (2026) · medRxiv · doi:10.64898/2026.05.21.26353338 · Cited by 1
Weniger Gewichtszunahme bei adipösen Schwangeren mit Metformin
Stupin, J. H. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0867-3
Maternal Metabolic State and Cancer Risk: An Evolving Manifestation of Generational Impact
Simmen, F. A., Heard, M. E., Pabona, J. M. P., Fernandes, L. M., Mercado, C. P., & Simmen, R. C. M. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6386-7_13
OS EFEITOS DA METFORMINA NA OBESIDADE DA GESTANTE E NO PESO DO RECÉM-NASCIDO
do Nascimento, I. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., & Silva, J. C. (2017) · Saúde e Pesquisa · doi:10.17765/1983-1870.2017v10n2p373-382
Hypothalamic pituitary adrenal axis dysregulation in obese pregnancy
Stirrat, L. (2018) · ERA
Schwangerschaft und Geburt bei Adipositas
Stubert, J. (2019) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-0840-7822
Maxwell, C. V., Gaudet, L., Cassir, G., Nowik, C. M., McLeod, N., Jacob, C.-É., & WALKER, M. C. (2019) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2019.08.035
Polycystic Ovarian Syndrome and Diabetes Mellitus
Nasr, M. Y., Alhuqayl, T. A., Alshammari, H. A., Alkhudhayri, H., Alzin, M. B., & Sulimani, R. A. (2021) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_140_20
Gestationsdiabetes und polyzystisches Ovarialsyndrom
Kollmann, M. (2021) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-021-00143-y
Pregnancy Outcome and Metabolic Syndrome
Ottanelli, S., Simeone, S., Serena, C., Rambaldi, M. P., Zullino, S., & Mecacci, F. (2021) · ISGE series · doi:10.1007/978-3-030-63650-0_13
Managing Gestational Diabetes During and After Pregnancy
Egan, A. M., & Dunne, F. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch6
Prediction and Prevention of Preeclampsia
Staff, A. C., Umans, J. G., & Jeyabalan, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818417-2.00013-0
Prevention of gestational diabetes mellitus: a minireview
D'Anna, R. (2022) · Italian Journal of Gynaecology and Obstetrics · doi:10.36129/jog.2022.28
Prädisposition/Phänotypen des Gestationsdiabetes mellitus
Kleinwechter, H. J., Demandt, N., & Nolte, A. (2021) · Frauenheilkunde up2date · doi:10.1055/a-1511-0722
Adipositas und Schwangerschaftsrisiken
Weichert, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-61906-3_6
Samy, A., Aleem, A. A. E., & Hassan, A. A.-E. (2023) · Evidence Based Women s Health Journal · doi:10.21608/ebwhj.2023.196608.1238
Maternal Obesity and ADHD: An Original Review of Evidence and Potential Mechanisms
Boueri, M. G., Fakhouri, M., Aoun, C., & Matar, M. (2023) · The Journal of Pediatric Academy · doi:10.4274/jpea.2023.256
Agents anti-hyperglycémiants oraux et grossesse
Cosson, E., Pinto, S., Rezgani, I., Barka, I., Sal, M., Zerguine, M., Tatulashvili, S., & Bihan, H. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.003
Enrique Valdés, R. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006121
Demidova, T. Y., Teplova, A. S., & Степанова, Е. В. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-449
Emerging Preventive Strategies for Preeclampsia
Provinciatto, H. G., Júnior, E. A., & Granese, R. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5112272
Enrique Valdés, R. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1007644
Amica-Carpenter, A., Cox, D. R., Sylvestre, Y., Roberts, S. A., Perchard, R., Calloway, E., Richardson, K., & Myers, J. (2025) · Trials · doi:10.1186/s13063-025-09154-5
Snell, K. I. E., Allotey, J., Smuk, M., Hooper, R., Chan, C., Ahmed, A., Chappell, L. C., Von Dadelszen, P., Green, M., Kenny, L. C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13175531
Self-citationLin, S.-F., Chang, S.-H., Kuo, C.-F., Lin, W.-T., Chiou, M.-J., & Huang, Y.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12922819
Poprzeczny, A. J., Louise, J., Deussen, A. R., & Dodd, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.12955783
Choudhary, N., & Kriplani, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010019
Ji, H., Wu, Y., Wu, S., Sun, X., Yu, Y., Hou, L., Zhao, R., Wang, C., Yu, Y., Ge, Y., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113118
Abdali, A. M., Tauma, R. J., Hussein, S. R. M., AlAasam, A. I., & Nasrawi, A. J. M. (2026) · International Journal of Clinical Obstetrics and Gynaecology Nexovation · doi:10.54660/.ijcogn.2026.2.2.35-40
Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review
Ivanović, K., Dugalić, S., Gojnić-Dugalić, M., & Milinčić, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166423
Metformin Exposure in Pregnancy and Fetal Programming: A Focused Review of Contemporary Evidence
Gojnić-Dugalić, M., Dugalić, S., Milinčić, M., & Ivanović, K. (2026) · Biomedicines · doi:10.3390/biomedicines14081867
Lopes, B. C., de Oliveira, N. M. L., Araújo, V. D. C., & Cruz, F. J. (2026) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2026rbgo46
Maternal metformin treatment in obese pregnant dams normalizes neonatal sensory-motor reflexes
Müller-Limberger, E., Frederick, B., Hansen, S., Wohlfarth, M., Janoschek, R., Mahabir, E., Fischer, P., Gründemann, D., Kalis, S., Alcazar, M. A. A., et al. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-026-00259-8
Fuglsang, J., Kampmann, U., Johnsen, S. K., McIntyre, D. H., & Ovesen, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13265-0.00007-0
Trouva, A., Vanky, E., Alvarsson, M., Calissendorff, J., Åsvold, B. O., Ujvári, D., & Hirschberg, A. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1884684
Perichart‐Perera, O., Hernández‐Hernández, L., & Rodríguez-Cano, A. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71471
Metadata
- Authors
- Chiswick, C., Reynolds, R. M., Denison, F., Drake, A. J., Forbes, S., Newby, D. E., Walker, B. R., Quenby, S., Wray, S., Weeks, A., Lashen, H., Rodriguez, A., Murray, G., Whyte, S., & Norman, J. E.
- Affiliations
- MRC Centre for Reproductive Health (GB)
- British Heart Foundation Centre for Cardiovascular Science (GB)
- Edinburgh Royal Infirmary (GB)
- University of Warwick (GB)
- Liverpool Women's Hospital (GB)
- Jessop Hospital (GB)
- University of Edinburgh (GB)
- Corresponding author
- Norman, Jane E
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 3
- Issue
- 10
- Pages
- 778-786
- ISSN
- 2213-8587 (ISSN-L)
- PMC
- PMC4673088
- OpenAlex
- W2144199745
- Cited by
- 260
- References
- 36
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 15 · 2023: 21 · 2022: 21 · 2021: 27 · 2020: 28 · 2019: 28 · 2018: 33 · 2017: 22 · 2016: 27 · 2015: 6
- FWCI
- 33.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Bristol Research (University of Bristol) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (103782)
- National Institute for Health and Care Research (08/246/09)
- Medical Research Council (MC_G1002463)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Keywords
- metformin, maternal obesity, pregnancy, birth weight, insulin resistance, miscarriage, stillbirth, preterm birth, gestational diabetes mellitus, maternal hyperglycemia, placental growth factor, placental insufficiency, fetal growth restriction, placental DNA methylation, epigenetics
- MeSH terms
- Abortion, Spontaneous, Adult, Double-Blind Method, Female, Fetal Macrosomia, Humans, Hypoglycemic Agents, Metformin, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Diabetes, Gestational, Stillbirth, Young Adult, Obesity, Abdominal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
